Project Grant HT94252510346
Award Date
5/1/25
Completion Date
7/31/27
Dollars Obligated
$320K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This $834,798 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports PET imaging research of HIF 2A in renal cancer at The University of Texas Southwestern Medical Center in Dallas, Texas. The research project aims to develop new diagnostic and treatment approaches for kidney cancer, which is a key focus area for this Defense Department program. The award will fund basic, translational, and clinical research...
The U.S. Department of Defense's Defense Health Agency awarded a $395,202 Project Grant to The University of Texas Southwestern Medical Center in Dallas, Texas under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "PET IMAGING OF HIF 2A IN RENAL CANCER," supports research to develop new imaging techniques for detecting and monitoring kidney cancer in military personnel and veterans. The three-year award, running from September 1, 2023 to August...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,107,000 three-year Project Grant to The University of Texas Southwestern Medical Center in Dallas, TX. The grant, effective September 1, 2023, will fund research to characterize the epigenetic and metabolic vulnerabilities in clear cell renal cell carcinoma (ccRCC) with VHL gene deficiencies, and explore the therapeutic potential of these findings. The University of Texas System will...
The Department of the Army Medical Command awarded a $1,189,000 Project Grant to The University of Texas Southwestern Medical Center through the Military Medical Research and Development program (CFDA 12.420) to support research titled "RECURRENT GENOMIC ALTERATIONS DRIVING CLEAR CELL RENAL CELL CARCINOMA DEVELOPMENT." The grant period runs from August 1, 2022 to July 31, 2026. The Military Medical Research and Development program aims to advance biomedical research that transforms...
This federal Project Grant award for $968,904.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research at the University of Texas Southwestern Medical Center (UT Southwestern) to target the DNA damage response as a potential treatment for clear cell renal cell carcinoma. The project will be conducted at UT Southwestern's facilities in Dallas, Texas over a 4-year period from July 1, 2024 to June 30, 2028. This...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
This Project Grant award of $1,106,902.00 was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The award supports research at the University of Texas Southwestern Medical Center in Dallas, Texas to "delineate tumor-immune contexture that shapes clear cell renal cell carcinoma (ccRCC) metastatic progression and response to immunotherapy." The 3-year project aims to advance the understanding of the tumor-immune...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $319,798 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) on April 15, 2024. The grant supports UT Southwestern's research to dissect unconventional mechanisms of action and resistance to rapalogs, a class of drugs, in renal cell carcinoma. The research aims to make significant advances in military medicine by improving...
This Project Grant award, valued at $159,341 and awarded on September 30, 2024, is funded through the Military Medical Research and Development program (CFDA 12.420) of the U.S. Department of the Army Medical Command. The grant supports research at The University of Texas Southwestern Medical Center in Dallas, Texas to target the PARP1 protein as a means of overcoming castration resistance in prostate cancer. The research aims to advance new treatment approaches for this condition, which is a...
This $1,189,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) aims to target stem-like CD8 T cells in immunotherapy against kidney cancer. The grant was awarded on September 1, 2023 to The University of Texas Southwestern Medical Center, an academic medical institution and component of the University of Texas System, to be completed by August 31, 2027. Through this funding, UT Southwestern will conduct research...